Skip to main content

Market Overview

Johnson & Johnson Set To Resume COVID-19 Vaccine Rollout In Europe — With A Warning On The Label

Johnson & Johnson Set To Resume COVID-19 Vaccine Rollout In Europe — With A Warning On The Label

Johnson & Johnson (NYSE: JNJ) said Tuesday that the European rollout of its COVID-19 vaccine is set to continue after it got the go-ahead from the regulator on the continent.

What Happened: The multinational pharmaceutical giant said in a statement that the European Medical Agency’s Pharmacovigilance Risk Assessment Committee had given updated guidance for the use of its COVID-19 vaccine.

The EMA said that the “overall benefit-risk profile remains positive.” 

The guidance comes after the PRAC reviewed a “small number of cases of a very rare adverse event involving blood clots in combination with low platelet counts that can occur within approximately one to three weeks following injection with the Company's COVID-19 vaccine,” said Johnson & Johnson.

As a result of the guidance, Johnson & Johnson will update the vaccine’s Summary of Product Characteristics and Package Leaflet to include information on diagnosis and management of adverse effects.

Why It Matters: Johnson & Johnson said it will resume the shipment of the vaccine in the European Union, Norway and Iceland.

In the United States, authorities in multiple states halted the distribution of Johnson & Johnson’s vaccine due to concerns about adverse reactions earlier in the month.

Last week, the company’s stock fell — leading to buying by bulls — after the U.S. Centers for Disease Control and Prevention and the Food and Drug Administration recommended that the use of Johnson & Johnson’s COVID-19 vaccine be paused in the country

See Also: US Puts Johnson & Johnson In Charge Of Troubled Vaccine Plant In Baltimore, Removes AstraZeneca

This month, the EMA concluded that there are possible links between the COVID-19 vaccine made by AstraZeneca Plc (NYSE: AZN) and blood clots. The agency said these should be listed as a “very rare side effect.”

On Tuesday, Johnson & Johnson reported $100 million in COVID-19 vaccine sales and better than expected Q1 earnings of $2.59 per share, up 12.6% on a year-over-year basis. The earnings beat estimates of $2.34 per share.

Price Action: Johnson and Johnson shares closed 2.33% higher at $166.48 on Tuesday and fell 0.2% in the after-hours trading.

For news coverage in Italian or Spanish, check out Benzinga Italia and Benzinga España.


Related Articles (JNJ)

View Comments and Join the Discussion!

Posted-In: Coronavirus Covid-19 EMA Europe VaccinesBiotech News General Best of Benzinga

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at